Actualités

Eli Lilly's spate of acquisitions is building out multiple areas of its pipeline at once.

These three penny stocks under $5 generate real revenue and have catalysts that analysts believe could drive significant upside

With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out.

Despite several setbacks over the past year, the drugmaker marches on.

These companies don't typically compete directly with one another, but that might change soon.

On June 18, Cathie Wood’s ARK Invest showed off a notable rotation following a superb run in two of the most popular high-growth stocks. Investors had been rewarding Robinhood (HOOD) for its cost-cutting plan and Roku (ROKU) for its takeover-driven rally, but ARK moved in the opposite direction. ...

Eli Lilly (NYSE:LLY) just reported a quarter that should have sent bulls into a frenzy. Revenue grew 55.5% year over year to $19.80 billion, Mounjaro alone delivered $8.66 billion, and management raised full-year guidance to $82 to $85 billion. Yet shares are up just 2.57% year to date at $1,098.57. That disconnect is the entire ... Prediction: Eli Lilly Will Trade at $1,200 on This Date

Cathie Wood Snaps Up $35 Million in Snowflake, Slashes Roku Stake

ARK shifts exposure toward growth and cloud

The foundation behind Novo Nordisk is funding a new effort to turn scientific discoveries into treatments.

By incorporating nonclinical testing services, the partnership seeks to standardise testing protocols across organisations.

RLTs were a hot topic at ASCO 2026, but experts note that certain limitations must be addressed to facilitate their widespread use in cancer care.

AI's next winners in healthcare could be companies like Eli Lilly and Twist Bioscience.

Ricks has led a $50 billion manufacturing Marshall Plan in pharma to safeguard Lilly’s lead in obesity and diabetes treatments.

Eli Lilly (LLY) closed at $1 in the latest trading session, marking a -1.19% move from the prior day.

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy, according to billionaire Ray Dalio’s Bridgewater Associates. On June 10, the US Food and Drug Administration approved a new dosing regimen for Eli Lilly and Company (NYSE:LLY) in the treatment of patients with moderate to severe atopic dermatitis. The new dosing […]

Eli Lilly is no stranger to the ranks of strong leaders. From the end of 2019 through July 2024, Eli Lilly gained more than 600% with a compound annual growth rate over 55%. Eli Lilly started as a half position but on the follow-up strength the next day, we brought it to a full position (4).

Eli Lilly (LLY) continues to attract attention as investors reassess the stock after recent trading, with shares last closing at US$1,112. With no single headline event, the focus shifts toward fundamentals and recent return patterns. See our latest analysis for Eli Lilly. For context, Eli Lilly’s recent pullback of around 0.9% on the day and 2.1% over the past week comes after a strong 12.5% 1 month share price return and a 42.7% 1 year total shareholder return. This suggests longer term...

FDA accepts RHHBY filing for Lunsumio VELO plus Polivy in relapsed or refractory LBCL as a potential chemotherapy-free treatment option.

After a few days of purging, the Ark Invest growth investor is buying stocks again.

PFE is betting on monthly obesity treatments and new oral programs to challenge LLY and NVO in a market projected to hit $120 billion by 2035.

Wegovy pill's U.K. approval gives Novo Nordisk its first European launch path ahead of wider EU approval as it seeks growth amid mounting pricing and competitive pressures.

BIIB is set to acquire RayThera for up to $1 billion, adding anti-inflammatory candidates that could expand its immunology pipeline and future growth.

Eli Lilly and Company (NYSE:LLY) is among the stocks with the best earnings growth for the next 3 years. On June 15, Eli Lilly and Company (NYSE:LLY) shared new data from the Phase 1 AJX-101 study. The study showed that an investigational type II JAK2 inhibitor delivered an “encouraging” safety profile, demonstrating clinical activity in […]

Johnson & Johnson has no plans to enter the booming obesity market, opting instead to focus on diseases such as cancer, CEO Joaquin Duato said in an interview for an upcoming episode of The David Rubenstein Show: Peer to Peer Conversations. The comments set J&J apart from many of its rivals that are trying to develop or acquire obesity medicines following blockbuster weight-loss drugs from Eli Lilly & Co. and Novo Nordisk.

Johnson & Johnson is focusing on oncology and neuroscience instead of obesity drugs, with AI possibly supporting its next growth cycle.

Management raised the bar, the stock rocketed higher, and now everyone is wondering if this is the new normal or just a sugar high.

The company is promising a new era of accelerated growth, but the trajectory of one key cancer drug holds a subtle warning for investors.

Eli Lilly and Company (NYSE:LLY) was among Jim Cramer’s stock calls on Mad Money, as he highlighted worthy space players and reviewed several of this year’s IPOs. When a caller noted the high share price and ventured a guess that the company might split the stock, Cramer commented: I don’t know if they’re going to […]

Eli Lilly (NYSE:LLY) plans to reduce its previously announced €2.7b investment in Germany by half. The company links the cutback to European drug pricing reforms that it says could affect future R&D and manufacturing commitments. The decision highlights rising friction between large pharmaceutical companies and European governments over efforts to limit healthcare spending. Eli Lilly is a major global pharmaceutical company with a broad portfolio of branded drugs and a pipeline of new...